LOX-1+ PMN-MDSCs from NPC survivors with CHB and those from CHB patients had higher NOX2 mRNA levels compared with LOX-1-CD15+ PMNs (Figure 3A); To confirm these results, the DCFDA method was used to determine the ROS level of LOX-1+ PMN-MDSCs and demonstrated that LOX-1+ PMN-MDSCs from NPC survivors with CHB and patients with CHB had elevated levels of ROS (Figure 3C). This evidence concerns the gene CYBB and nasopharyngeal carcinoma.